Kopran Ltd.
Snapshot View

217.55 -9.55 ▼-4.2%

25 May 2022, 04:01:00 PM
Volume: 7,692

Overview View Details

Sector Healthcare Compare with Sector peers
Industry Pharmaceuticals & Drugs Compare with Industry peers
Website http://www.kopran.com
Market Cap 1,048.34 Cr.
Enterprise Value(EV) 1,126.19 Cr. 2021-09
Financial Indicators
Earnings per share (EPS) 12.15 Trailing Twelve Months Ending 2021-12
Price-Earning Ratio (PE) 17.91 Trailing Twelve Months Ending 2021-12
Industry PE 28.07 Trailing Twelve Months Ending 2021-12
Book Value / Share 84.78 Trailing Twelve Months Ending 2021-12
Price to Book Value 2.57 Calculated using Price: 217.55
Dividend Yield 0.69 Period Ending 2021-03
No. of Shares Subscribed 4.82 Cr. 48,210,605 Shares
FaceValue 10
Company Profile

The company was incorporated on April 26, 1958 as a private limited company under the name Kopran Chemical Company Pvt. Ltd. by Ramanlal V Shah Sevantilal, A Shah , Chimanlal G Sheth and Jivanalal M Shah. In 1972, the company’s management was acquired by Chemo Pharma Laboratories Ltd and the Company’s products were marketed by them.

Promoted by the Parijat Enterprises, Kopran is currently an integrated health care company. Kopran has used research-based technology to contribute towards total health-care. The company started modestly as a Semi Synthetic Penicillin (SSP) player and expanded to becomes the largest SSP Player in India with an annual SSP facility of over 1200 tones per annum.Subsequently the SSP business was hived off into a separate Company in a joint venture with Synpac Pharmaceuticals Ltd, UK.Kopran Laboratories Ltd. markets and supports high-tech life-saving medical equipments and diagnostics reagents since 1988.

Kopran Research Laboratories Ltd. (KRLL) is an emerging research organisation with particular interests in the areas of drug discovery, polymer technology and synthesis of new molecules.

Kopran is working towards creating and maintaining a global presence.Presence in Africa through Kampala Pharmaceutical Industries (KPI),a pharmaceutical company engaged in the manufacture and marketing of finished dosage forms in Uganda.

The company is having presence in the Middle East Market through a joint venture with Dubai Investment Corporation a leading investment company in Dubai for the manufacture and marketing of finished dosage forms in Dubai.

KRLL is a 100% subsidiary of Kopran Ltd.  KRLL is recognised by the Department of Science and Industrial Research (DSIR), Government of India. The company is staffed with competent and dedicated team of scientists.

Product range of the company includes:

Finished Dosage Forms

  • Antibiotics/antibacterials
  • Anti-malarial
  • Cadiovasculars
  • Pain management
  • Anthelminthics
  • Antiprotozoals
  • Antidiabetics
  • Gastrointestinals
  • Drug for erectile dysfuntion
  • Antiallergics
  • Respiratory/anti-asthmatics
  • Metered dose inhalers
  • Dry powder inhalers
  • Antiviral

Active Pharmaceutical Ingredients

  • Anti-hypertensives
  • Macrolides
  • Taste Masked
  • Cephalosporins 
  • Under Development
  • Others

Achievements/ recognition:

  • Kopran has a state of art manufacturing plants (Penicillin & General) approved by: -MCC (South Africa) -TGA, Australia and FDA, USA are in the pipeline

Future plans:

  • Brand Equity Development
  • Research for New Chemical Entities
  • Globalise its operations thus making Kopran a truly International Pharmaceutical Company.

Delivery View Details

Delivered Qty
Traded Qty

Performance View Details

1 Day
-4.21%
1 Week
-4.98%
1 Month
-19.26%
3 Month
-21.72%
6 Month
-15.76%
1 Year
+10.15%
2 Year
+686.80%
5 Year
+155.79%
10 Year
+1421.33%
9 years 2013-03 2014-03 2015-03 2016-03 2017-03 2018-03 2019-03 2020-03 2021-03
Return on Equity (%) 13.39 17.65 -43.06 12.19 17.71 15.21 15.34 11.74 28.34
Return on Capital Employed (%) 11.81 14.27 -12.48 13.09 19.24 13.88 16.30 13.69 30.40
Return on Assets (%) 4.33 6.11 -13.63 3.98 7.15 6.77 7.27 5.84 15.22

Balance Sheet View Details

Particulars 10 years 2013-03 Rs. Cr. 2014-03 Rs. Cr. 2015-03 Rs. Cr. 2016-03 Rs. Cr. 2017-03 Rs. Cr. 2018-03 Rs. Cr. 2019-03 Rs. Cr. 2020-03 Rs. Cr. 2021-03 Rs. Cr. 2021-09* Rs. Cr.
Shh. Funds 97 115 99 109 125 145 168 190 245 262
Non Curr. Liab. 73 67 18 33 32 31 46 40 34 34
Curr. Liab. 93 117 158 122 136 136 135 140 161 193
Minority Int.
Equity & Liab. 263 299 275 264 293 312 349 370 439 489
Non Curr. Assets 141 139 105 110 114 118 142 148 162 175
Curr. Assets 123 160 170 154 180 194 208 223 277 314
Misc. Exp. not W/O
Total Assets 263 299 275 264 293 312 349 370 439 489

Profit Loss View Details

Particulars 10 years 2013-03 Rs. Cr. 2014-03 Rs. Cr. 2015-03 Rs. Cr. 2016-03 Rs. Cr. 2017-03 Rs. Cr. 2018-03 Rs. Cr. 2019-03 Rs. Cr. 2020-03 Rs. Cr. 2021-03 Rs. Cr. 2021-12 Rs. Cr. TTM
Net Sales 250 303 326 296 310 313 358 360 492 475
Other Income 2 2 7 2 11 11 4 1 18 14
Total Income 252 305 332 299 320 324 362 360 510 489
Total Expenditure -217 -260 -294 -266 -274 -284 -312 -313 -410 -395
PBIDT 35 45 38 33 47 40 49 47 100 94
Interest -12 -14 -13 -13 -14 -9 -9 -9 -6 -5
Depreciation -12 -13 -10 -8 -8 -9 -9 -10 -10 -11
Taxation -5 -2 -8 -7 -22 -19
Exceptional Items -54 -1 -1
PAT 11 17 -39 11 20 20 24 21 62 59
Minority Interest
Share Associate
Other Related Items
Consolidated Net Profit 11 17 -39 11 20 20 24 21 62 59
Adjusted EPS 3 4 -10 2 5 5 6 5 14 14

Cash Flow View Details

Particulars 10 years 2012-03 Rs. Cr. 2013-03 Rs. Cr. 2014-03 Rs. Cr. 2015-03 Rs. Cr. 2016-03 Rs. Cr. 2017-03 Rs. Cr. 2018-03 Rs. Cr. 2019-03 Rs. Cr. 2020-03 Rs. Cr. 2021-03 Rs. Cr.
Cash Fr. Operatn. 35 15 3 46 29 16 26 25 31 60
Cash Fr. Inv. -10 -9 -9 -10 -9 -18 -11 -25 -13 -24
Cash Fr. Finan. -19 -12 7 -37 -19 2 -15 -1 -18 -35
Net Change 6 -7 0 0 0 0 0 0 0 1
Cash & Cash Eqvt 7 1 1 1 1 1 0 0 1 2

Shareholding Pattern View Details

9 Qtrs 2020-03 (%) 2020-06 (%) 2020-09 (%) 2020-12 (%) 2021-03 (%) 2021-06 (%) 2021-09 (%) 2021-12 (%) 2022-03 (%)
Promoter 43.78 43.78 43.78 43.78 43.78 43.78 43.78 43.78 44.25
Public 56.22 56.22 56.22 56.22 56.22 56.22 56.22 56.22 55.75
Depository Receipts 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Promoter Holding Pledge (%) 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00

Announcements View Details

Fri, 20 May 2022
Announcement under Regulation 30 (LODR)-Credit Rating
Credit Rating-Reaffirmed.
Fri, 13 May 2022
Board Meeting Intimation for Board Meeting For Approval Of Financial Results For The Year Ended 31St March 2022.
KOPRAN LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 27/05/2022 inter alia to consider and approve Standalone and Consolidated Audited Financial Result of the Company for the Quarter and Financial Year ended March 31 2022 & recommend Dividend (if any)
Fri, 13 May 2022
Board to consider Dividend
Kopran Ltd has informed BSE that the Meeting of the Board of Directors of the Company is scheduled to be held on May 27 2022 to inter alia consider and approve and take on record the following:

1. Standalone and Consolidated Audited Financial Result of the Company for the Quarter and Financial Year ended March 31 2022.

2. Recommend Dividend (if any)

Further pursuant to the Companys Code of Conduct for Regulating & Reporting of Trading by Insiders and for Fair Disclosure the Trading Window for dealing in the securities of the Company which was closed from April 01 2022 will re-open 48 hours after the declaration of the financial results.

Technical Scans View Details

Wed, 25 May 2022
Opening at High Opening at High
Closing Below Previous Low Closing Below Previous Low
Making Lower Lows for 3 days Making Lower Lows for 3 days
High Decrease 1 Month High Decrease 1 Month
High Decrease 3 Months High Decrease 3 Months

Related Stocks View Details

Stock Name Market Cap(Rs. Cr.) LTP Chg %
Sun Pharmaceutical Industries Ltd. 218,615.41 911.15 +0.1%
Divi's Laboratories Ltd. 93,410.43 3,518.70 -3.9%
Cipla Ltd. 78,373.92 971.35 +0.1%
Dr. Reddy's Laboratories Ltd. 71,774.48 4,312.70 -0.9%
Apollo Hospitals Enterprise Ltd. 50,694.88 3,525.75 -2.9%
Gland Pharma Ltd. 45,552.31 2,767.85 -3.6%
Torrent Pharmaceuticals Ltd. 44,253.16 2,615.30 +0.9%
Stock Name Statement TTM Ending Price Earning Ratio(TTM) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2021-12 33.92 911.15 +0.1%
Divi's Laboratories Ltd. Consolidated 2022-03 31.55 3,518.70 -3.9%
Cipla Ltd. Consolidated 2022-03 31.14 971.35 +0.1%
Dr. Reddy's Laboratories Ltd. Consolidated 2022-03 32.89 4,312.70 -0.9%
Apollo Hospitals Enterprise Ltd. Consolidated 2021-12 44.73 3,525.75 -2.9%
Gland Pharma Ltd. Consolidated 2022-03 37.59 2,767.85 -3.6%
Torrent Pharmaceuticals Ltd. Consolidated 2021-12 36.30 2,615.30 +0.9%
Stock Name Statement TTM Ending Price To Book Value(TTM) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2021-12 4.23 911.15 +0.1%
Divi's Laboratories Ltd. Consolidated 2022-03 7.96 3,518.70 -3.9%
Cipla Ltd. Consolidated 2022-03 3.76 971.35 +0.1%
Dr. Reddy's Laboratories Ltd. Consolidated 2022-03 3.74 4,312.70 -0.9%
Apollo Hospitals Enterprise Ltd. Consolidated 2021-12 9.16 3,525.75 -2.9%
Gland Pharma Ltd. Consolidated 2022-03 6.36 2,767.85 -3.6%
Torrent Pharmaceuticals Ltd. Consolidated 2021-12 6.84 2,615.30 +0.9%
Stock Name Statement Year Ending Debt Equity Ratio LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2021-03 0.08 911.15 +0.1%
Divi's Laboratories Ltd. Consolidated 2021-03 0.00 3,518.70 -3.9%
Cipla Ltd. Consolidated 2021-03 0.10 971.35 +0.1%
Dr. Reddy's Laboratories Ltd. Consolidated 2021-03 0.17 4,312.70 -0.9%
Apollo Hospitals Enterprise Ltd. Consolidated 2021-03 0.62 3,525.75 -2.9%
Gland Pharma Ltd. Consolidated 2021-03 0.00 2,767.85 -3.6%
Torrent Pharmaceuticals Ltd. Consolidated 2021-03 0.84 2,615.30 +0.9%
Stock Name Statement Year Ending Return On Equity(%) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2021-03 4.98 911.15 +0.1%
Divi's Laboratories Ltd. Consolidated 2021-03 23.90 3,518.70 -3.9%
Cipla Ltd. Consolidated 2021-03 14.13 971.35 +0.1%
Dr. Reddy's Laboratories Ltd. Consolidated 2021-03 11.53 4,312.70 -0.9%
Apollo Hospitals Enterprise Ltd. Consolidated 2021-03 3.44 3,525.75 -2.9%
Gland Pharma Ltd. Consolidated 2021-03 20.97 2,767.85 -3.6%
Torrent Pharmaceuticals Ltd. Consolidated 2021-03 23.49 2,615.30 +0.9%
Stock Name Statement Year Ending Return On Capital Employed(%) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2021-03 4.98 911.15 +0.1%
Divi's Laboratories Ltd. Consolidated 2021-03 23.90 3,518.70 -3.9%
Cipla Ltd. Consolidated 2021-03 14.13 971.35 +0.1%
Dr. Reddy's Laboratories Ltd. Consolidated 2021-03 11.53 4,312.70 -0.9%
Apollo Hospitals Enterprise Ltd. Consolidated 2021-03 3.44 3,525.75 -2.9%
Gland Pharma Ltd. Consolidated 2021-03 20.97 2,767.85 -3.6%
Torrent Pharmaceuticals Ltd. Consolidated 2021-03 23.49 2,615.30 +0.9%
Stock Name Statement Year Ending Net Sales(Rs. Cr.) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2021-03 33,498.14 911.15 +0.1%
Divi's Laboratories Ltd. Consolidated 2021-03 6,969.40 3,518.70 -3.9%
Cipla Ltd. Consolidated 2021-03 19,159.59 971.35 +0.1%
Dr. Reddy's Laboratories Ltd. Consolidated 2021-03 19,047.50 4,312.70 -0.9%
Apollo Hospitals Enterprise Ltd. Consolidated 2021-03 10,560.00 3,525.75 -2.9%
Gland Pharma Ltd. Consolidated 2021-03 3,462.88 2,767.85 -3.6%
Torrent Pharmaceuticals Ltd. Consolidated 2021-03 8,004.83 2,615.30 +0.9%
Stock Name Statement Year Ending Profit After Tax(Rs. Cr.) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2021-03 2,284.68 911.15 +0.1%
Divi's Laboratories Ltd. Consolidated 2021-03 1,984.29 3,518.70 -3.9%
Cipla Ltd. Consolidated 2021-03 2,401.30 971.35 +0.1%
Dr. Reddy's Laboratories Ltd. Consolidated 2021-03 1,903.60 4,312.70 -0.9%
Apollo Hospitals Enterprise Ltd. Consolidated 2021-03 136.00 3,525.75 -2.9%
Gland Pharma Ltd. Consolidated 2021-03 996.96 2,767.85 -3.6%
Torrent Pharmaceuticals Ltd. Consolidated 2021-03 1,251.88 2,615.30 +0.9%